Why I’m Bullish on $GOSS: The Road to Phase 3 PROSERA

Gossamer Bio is currently sitting at a massive inflection point. If you aren’t watching this ticker, here is the breakdown of why the sentiment is turning heavily bullish:

1. The "Big One" is Coming ⏱️

Everything hinges on the Phase 3 PROSERA trialfor seralutinib. Data readout is expected in February 2026. This is a first-in-class inhaled treatment for Pulmonary Arterial Hypertension (PAH)—a multi-billion dollar market. Positive results would be a complete game-changer.

2. Proven Foundations 📈

This isn’t a blind gamble. The earlier Phase 2 TORREY trials already showed sustained clinical improvements. Furthermore, their partnership with the Chiesi Group provides the commercial muscle needed for a global rollout.

3. The Smart Money is In 🏦

Institutional ownership is sitting at roughly 81%. Big players like Vanguard and State Street have been holding/increasing positions, signaling that the "pros" are betting on a clinical win.

4. Analyst Consensus & Huge Upside 🎯

Wall Street is screaming "undervalued." The consensus is a Moderate Buy with price targets suggesting a potential 300%+ upside:

* Piper Sandler: $15.00

* Scotiabank: $11.00

* H.C. Wainwright: $10.00

* Barclays: $9.00

* Oppenheimer: $9.00

* Goldman Sachs: $8.00

* Wedbush: $5.00

Average Price Target: ~$9.00

Current Risk/Reward: Massive. With a target range of $5 to $15, the market is pricing in a major recovery upon successful data.

Bottom Line: $GOSS is a de-risking clinical play with top-tier institutional backing and a massive catalyst just around the corner.

Disclaimer: Not financial advice. Always do your own DD.